Eventide Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-4,475,054
| Closed | -$13.6M | – | 257 |
|
|
2024
Q4 | $13.6M | Sell |
4,475,054
-4,072,842
| -48% | -$12.3M | 0.25% | 118 |
|
|
2024
Q3 | $31.5M | Hold |
8,547,896
| – | – | 0.54% | 64 |
|
|
2024
Q2 | $35M | Sell |
8,547,896
-3,026,925
| -26% | -$12.4M | 0.6% | 56 |
|
|
2024
Q1 | $182M | Buy |
11,574,821
+14,846
| +0.1% | +$234K | 2.86% | 2 |
|
|
2023
Q4 | $175M | Buy |
11,559,975
+3,745,936
| +48% | +$56.8M | 2.86% | 3 |
|
|
2023
Q3 | $157M | Buy |
7,814,039
+936,236
| +14% | +$18.8M | 2.82% | 4 |
|
|
2023
Q2 | $194M | Buy |
6,877,803
+3,650,803
| +113% | +$103M | 3.28% | 1 |
|
|
2023
Q1 | $55.5M | Buy |
3,227,000
+1,070,485
| +50% | +$18.4M | 1.02% | 32 |
|
|
2022
Q4 | $43.4M | Buy |
2,156,515
+295,515
| +16% | +$5.95M | 0.86% | 41 |
|
|
2022
Q3 | $40.3M | Buy |
1,861,000
+857,000
| +85% | +$18.6M | 0.79% | 49 |
|
|
2022
Q2 | $28.2M | Buy |
1,004,000
+243,000
| +32% | +$6.83M | 0.6% | 58 |
|
|
2022
Q1 | $35.1M | Buy |
761,000
+232,000
| +44% | +$10.7M | 0.55% | 60 |
|
|
2021
Q4 | $44.5M | Hold |
529,000
| – | – | 0.57% | 60 |
|
|
2021
Q3 | $35.3M | Buy |
529,000
+108,600
| +26% | +$7.24M | 0.46% | 71 |
|
|
2021
Q2 | $22.4M | Sell |
420,400
-411,600
| -49% | -$21.9M | 0.3% | 89 |
|
|
2021
Q1 | $36.1M | Hold |
832,000
| – | – | 0.54% | 69 |
|
|
2020
Q4 | $43.2M | Sell |
832,000
-79,416
| -9% | -$4.12M | 0.66% | 55 |
|
|
2020
Q3 | $28.8M | Sell |
911,416
-3,289
| -0.4% | -$104K | 0.56% | 59 |
|
|
2020
Q2 | $42.5M | Buy |
+914,705
| New | +$42.5M | 0.92% | 38 |
|